Taken together, multiple DPYD variants have now been identified, for which an association with 5-FU toxicity has been replicated in multiple studies. In addition, a trend is observed that severe 5 ...

Vistogard effectively treats 5-FU chemotherapy toxicity Add topic to email alerts Please provide your email address to receive an email when new articles are posted on Cornea/External Disease in ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for uridine triacetate (Wellstat) as an antidote for patients at risk of serious toxicity following an ...

Under an expanded access protocol and under FDA emergency treatment provisions in the U.S., uridine triacetate is currently provided to patients at risk of excess 5-FU toxicity due to overdose and ...

The FDA has approved Wellstat Therapeutics' Vistogard (uridine triacetate) oral granules, the first treatment for patients following an overdose of 5-fluorouracil (5-FU) or capecitabine, ...

A bolus of 0.2 mL of Healon was injected, followed by 0.3 mL of 5-FU with a concentration of 50 mg/mL, injected with a 30-gauge needle entering through the bolus of Healon.

An unadjusted analysis showed no difference in OS between patients who received the 5-FU bolus and those who did not for colorectal cancer (23.6 vs 24.5 months), gastroesophageal cancer (10.4 vs ...

In an additional abstract published at ASCO, Wellstat will report data from a preclinical study examining the role of uridine triacetate in reversing 5-FU toxicity due to DPD deficiency. 6 Results ...

DPYD Promoter Hypermethylation & 5-FU Toxicity. An initial study suggested DPYD promoter hypermethylation as a potential important mechanism in 5-FU toxicity.